IFNA1 and Cirrhosis: The available data have shown that the efficacy and safety of DCV-based treatments in patients with cirrhosis are not significantly different from those obtained in non cirrhotic subjects, however there are limited data on IFN-free regimens in advanced liver disease, and the impact of HCV clearance on patients with decompensated cirrhosis as well as on patients awaiting liver transplantation needs further evaluation.